Research Progress of Drugs in Prevention and Treatment of Nephrolithiasis

Shasha XIA, Jun SHEN, Kaiwen SHEN, Qiang WANG, Weihu CEN

Acta Academiae Medicinae Sinicae ›› 2024, Vol. 46 ›› Issue (6) : 918-923.

PDF(781 KB)
Home Journals Acta Academiae Medicinae Sinicae
Acta Academiae Medicinae Sinicae

Abbreviation (ISO4): Acta Academiae Medicinae Sinicae      Editor in chief: Xuetao CAO

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(781 KB)
Acta Academiae Medicinae Sinicae ›› 2024, Vol. 46 ›› Issue (6) : 918-923. DOI: 10.3881/j.issn.1000-503X.15987
Review Articles

Research Progress of Drugs in Prevention and Treatment of Nephrolithiasis

Author information +
History +

Abstract

With the improvement of people’s living standards,the incidence of nephrolithiasis is increasing year by year.Nephrolithiasis poses a serious threat to the patients due to the unclear etiology,complicated composition of stones,and high recurrence rate after surgery.As the research on the pathogenesis and pathophysiology of nephrolithiasis keeps deepening in recent years,researchers have made achievements in the drug treatment,which has become a hot topic for urologists.This paper reviews the advances in the research on the possible formation mechanism and drug-induced litholysis and prevention for nephrolithiasis,aiming to provide theoretical references for subsequent clinical research.

Key words

nephrolithiasis / drug-induced litholysis / prevention and treatment

Cite this article

Download Citations
Shasha XIA , Jun SHEN , Kaiwen SHEN , et al . Research Progress of Drugs in Prevention and Treatment of Nephrolithiasis[J]. Acta Academiae Medicinae Sinicae. 2024, 46(6): 918-923 https://doi.org/10.3881/j.issn.1000-503X.15987

References

[1]
Ye Z, Zeng G, Yang H, et al. The status and characteristics of urinary stone composition in China[J]. BJU Int, 2020, 125(6):801-809.DOI:10.1111/bju.14765.
[2]
Bishop K, Momah T, Ricks J. Nephrolithiasis[J]. Prim Care, 2020, 47(4):661-671.DOI:10.1016/j.pop.2020.08.005.
[3]
Skolarikos A, Jung H, Neisius A, et al. EAU guidelines on urolithiasis[EB/OL]. [2024-09-11]. https://d56bochluxqnz.cloudfront.net/documents/pocket-guidelines/EAU-Pocket-on-Urolithiasis-2024.pdf
[4]
Ramos GK, Goldfarb DS. Update on uric acid and the kidney[J]. Curr Rheumatol Rep, 2022, 24(5):132-138.DOI:10.1007/s11926-022-01069-3.
[5]
Thomas H, Lazaros T, Bhaskar KS. Cystine stones:developments in minimally invasive surgery and their impact on morbidity and stone clearance[J]. Res Rep Urol, 2023, 15:175-185.DOI:10.2147/RRU.S381190.
[6]
Fontenelle LF, Sarti TD. Kidney stones:treatment and prevention[J]. Am Fam Physician, 2019, 99(8):490-496.
[7]
孙西钊. 枸橼酸氢钾钠防治尿石症研究进展[J]. 中华实验外科杂志, 2005, 22(9):1148-1149.DOI:10.3760/j.issn:1001-9030.2005.09.060.
[8]
Ren ST, Du YX, Xu CF, et al. Preventive and therapeutic effects of sodium bicarbonate on melamine-induced bladder stones in mice[J]. Urolithiasis, 2014, 42(5):409-414.DOI:10.1007/s00240-014-0689-5.
[9]
谢林国, 解海杰, 杨雄, 等. 枸橼酸氢钾钠在大负荷肾尿酸结石治疗中的应用(附6例报告并文献复习)[J]. 中华泌尿外科杂志, 2021, 42(1):33-37.DOI:10.3760/cma.j.cn112330-20200827-00626.
[10]
Halinski A, Bhatti KH, Boeri L, et al. Spectrum of bacterial pathogens from urinary infections associated with struvite and metabolic stones[J]. Diagnostics (Basel), 2022, 13(1):80.DOI:10.3390/diagnostics13010080.
[11]
Karki N, Leslie SW. Struvite and triple phosphate renal calculi[M]. Treasure Island (FL): Stat Pearls Publishing, 2023:1-13.
[12]
孙春悦, 张曦才, 李凤岳, 等. 感染性结石的治疗进展[J]. 中国医师杂志, 2023, 25(10):1593-1597.DOI:10.3760/cma.j.cn431274-20221107-01145.
[13]
Flannigan R, Choy WH, Chew B, et al. Renal struvite stones-pathogenesis,microbiology,and management strategies[J]. Nat Rev Urol, 2014, 11(6):333-341.DOI:10.1038/nrurol.2014.99.
[14]
张玉, 丁海琪. 芦根和虎杖水提液对不同类型尿路结石的体外溶石作用比较研究[J]. 实用医技杂志, 2016, 23(11):1183-1185.
[15]
Ji L, Shi W, Wang L, et al. Characterization of the chemical constituents and metabolic profile of Polygonum cuspidatum Sieb.et Zucc.in rat plasma,urine,and feces by ultra-high performance liquid chromatography coupled with Quadrupole-Exactive Orbitrap mass spectrometry[J]. J Sep Sci, 2022, 45(23):4292-4317.DOI:10.1002/jssc.202200522.
[16]
赵建一. 金钱草治疗尿结石的机理作用研究[J]. 中医临床研究, 2013, 5(16):37-38.DOI:10.3969/j.issn.1674-7860.2013.16.017.
[17]
曾进, 章咏裳, 胡仁昭, 等. 尿路梗阻与肾结石形成过程的研究[J]. 中华实验外科杂志, 1990, 7(2):72-73.DOI:10.3760/cma.j.issn.1001-9030.1990.02.115.
[18]
袁生泉, 邓小丽, 袁丽珍. 常规基础治疗联合微创手术引流在尿路梗阻继发感染中的治疗作用[J]. 黑龙江医药, 2019, 32(3):711-713.DOI:10.14035/j.cnki.hljyy.2019.03.100.
[19]
丛小明, 孙西钊, 顾晓箭. 泌尿系药物性结石研究进展[J]. 中华泌尿外科杂志, 2015, 36(3):237-240.DOI:10.3760/cma.j.issn.1000-6702.2015.03.023.
[20]
Ermer T, Nazzal L, Tio MC, et al. Oxalate homeostasis[J]. Nat Rev Nephrol, 2023, 19(2):123-138.DOI:10.1038/s41581-022-00643-3.
[21]
文天斌, 陈玉, 彭新庆, 等. 口服维生素B6、维生素E预防泌尿系草酸钙结石术后留置双J管附壁结石形成疗效研究[J]. 中国医药科学, 2023, 13(23):122-125.DOI:10.20116/j.issn2095-0616.2023.23.28.
[22]
Hoppe B, Martin-Higueras C. Improving treatment options for primary hyperoxaluria[J]. Drugs, 2022, 82(10):1077-1094.DOI:10.1007/s40265-022-01735-x.
[23]
Tang R, Jiang Y, Tan A, et al. 16S rRNA gene sequencing reveals altered composition of gut microbiota in individuals with kidney stones[J]. Urolithiasis, 2018, 46(6):503-514.DOI:10.1007/s00240-018-1037-y.
[24]
Paul E, Albert A, Ponnusamy S, et al. Designer probiotic Lactobacillus plantarum expressing oxalate decarboxylase developed using group II intron degrades intestinal oxalate in hyperoxaluric rats[J]. Microbiol Res, 2018, 215:65-75.DOI:10.1016/j.micres.2018.06.009.
[25]
Nazzal L, Francois F, Henderson N, et al. Effect of antibiotic treatment on Oxalobacter formigenes colonization of the gut microbiome and urinary oxalate excretion[J]. Sci Rep, 2021, 11(1):16428.DOI:10.1038/s41598-021-95992-7.
[26]
Arvans D, Jung YC, Antonopoulos D, et al. Oxalobacter formigenes-derived bioactive factors stimulate oxalate transport by intestinal epithelial cells[J]. J Am Soc Nephrol, 2017, 28(3):876-887.DOI:10.1681/ASN.2016020132.
[27]
Anantharam V, Allison MJ, Maloney PC. Oxalate:formate exchange.The basis for energy coupling in Oxalobacter[J]. J Biol Chem, 1989, 264(13):7244-7250.
[28]
闫传武, 唐山川. 枸橼酸氢钾钠预防草酸钙结石复发30例临床研究[J]. 中国药业, 2018, 27(4):74-76.DOI:10.3969/j.issn.1006-4931.2018.04.025.
[29]
朱晓雨, 王安喜, 黄霆, 等. 葛根素治疗草酸钙结石80例临床观察[J]. 西北药学杂志, 2018, 33(5):655-657.DOI:10.3969/j.issn.1004-2407.2018.05.021.
[30]
Peerapen P, Thongboonkerd V. Kidney stone prevention[J]. Adv Nutr, 2023, 14(3):555-569.DOI:10.1016/j.advnut.2023.03.002.
[31]
Shi C, Zhou Z, Chi X, et al. Recent advances in gout drugs[J]. Eur J Med Chem, 2023, 245(Pt 1):114890.DOI:10.1016/j.ejmech.2022.114890.
[32]
邓耀良, 刘云龙, 陶芝伟, 等. 细胞-晶体反应介导的炎症在肾内草酸钙晶体形成中的作用[J]. 中华外科杂志, 2018, 56(10):733-736.DOI:10.3760/cma.j.issn.0529-5815.2018.10.004.
[33]
Jia Q, Huang Z, Wang G, et al. Osteopontin:an important protein in the formation of kidney stones[J]. Front Pharmacol, 2022(13):1036423.DOI:10.3389/fphar.2022.1036423.
[34]
Khan SR, Johnson JM, Peck AB, et al. Expression of osteopontin in rat kidneys:induction during ethylene glycol induced calcium oxalate nephrolithiasis[J]. J Urol, 2002, 168(3):1173-1181.DOI:10.1016/S0022-5347(05)64621-6.
[35]
Taguchi K, Okada A, Hamamoto S, et al. M1/M2-macrophage phenotypes regulate renal calcium oxalate crystal development[J]. Sci Rep, 2016(6): 35167.DOI:10.1038/srep35167.
[36]
Bulfone-Paus S, Paus R. Osteopontin as a new player in mast cell biology[J]. Eur J Immunol, 2008, 38(2):338-341.DOI:10.1002/eji.200738131.
[37]
Shinohara ML, Jansson M, Hwang ES, et al. T-bet-dependent expression of osteopontin contributes to T cell polarization[J]. Proc Natl Acad Sci U S A, 2005, 102(47):17101-17106.DOI:10.1073/pnas.0508666102.
[38]
Zhou J, Jin J, Li X, et al. Total flavonoids of desmodium styracifolium attenuates the formation of hydroxy-L-proline-induced calcium oxalate urolithiasis in rats[J]. Urolithiasis, 2018, 46(3):231-241.DOI:10.1007/s00240-017-0985-y.
[39]
才春东, 姜宁, 王国增, 等. 枸橼酸钾对大鼠肾草酸钙结石骨桥蛋白表达的影响[J]. 宁夏医科大学学报, 2010, 32(2):176-178,152.DOI:10.16050/j.cnki.issn1674-6309.2010.02.042.
[40]
卢灿峰, 李帅阳, 辛士永, 等. 二甲双胍通过调节骨桥蛋白和NF-κB通路表达抑制大鼠肾结石形成[J]. 热带医学杂志, 2021, 21(12):1517-1522,后插1.DOI:10.3969/j.issn.1672-3619.2021.12.005.
[41]
刘若天, 木拉提·马合木提, 郜乐, 等. 萝卜硫素通过Nrf2信号通路对大鼠草酸钙肾结石形成的作用和机制研究[J]. 现代生物医学进展, 2022, 22(11):2028-2033.DOI:10.13241/j.cnki.pmb.2022.11.005.
[42]
Zhu J, Wang Q, Li C, et al. Inhibiting inflammation and modulating oxidative stress in oxalate-induced nephrolithiasis with the Nrf2 activator dimethyl fumarate[J]. Free Radic Biol Med, 2019, 134:9-22.DOI:10.1016/j.freeradbiomed.2018.12.033.
[43]
邓茂放, 陈彤, 王会镇, 等. 乌梅提取物对肾结石模型大鼠肾功能的保护作用及机制研究[J]. 中国临床药理学杂志, 2018, 34(15):1872-1874,1885.DOI:10.13699/j.cnki.1001-6821.2018.15.039.
[44]
王美才, 储传敏, 程文, 等. 老年前列腺增生症术后尿路感染以及细胞炎性机制分析[J]. 临床外科杂志, 2020, 28(11):1066-1069.DOI:10.3969/j.issn.1005-6483.2020.11.020.
[45]
Ye T, Yang X, Liu H, et al. Theaflavin protects against oxalate calcium-induced kidney oxidative stress injury via upregulation of SIRT1[J]. Int J Biol Sci, 2021, 17(4):1050-1060.DOI:10.7150/ijbs.57160.
PDF(781 KB)

Accesses

Citation

Detail

Sections
Recommended

/